Humacyte (NASDAQ:HUMA) CFO Dale Sander Sells 45,887 Shares

Humacyte, Inc. (NASDAQ:HUMA) CFO Dale Sander sold 45,887 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $0.90, for a total transaction of $41,298.30. Following the transaction, the chief financial officer owned 267,213 shares of the company’s stock, valued at $240,491.70. This trade represents a 14.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Humacyte Stock Performance

Humacyte stock opened at $0.92 on Thursday. The company’s 50-day moving average price is $0.84 and its 200-day moving average price is $1.04. Humacyte, Inc. has a twelve month low of $0.55 and a twelve month high of $2.93. The company has a quick ratio of 3.32, a current ratio of 3.93 and a debt-to-equity ratio of 5.46. The company has a market cap of $203.64 million, a PE ratio of -1.61 and a beta of 2.31.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The firm had revenue of $0.50 million during the quarter, compared to the consensus estimate of $1.46 million. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. On average, equities research analysts forecast that Humacyte, Inc. will post -0.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of HUMA. R Squared Ltd purchased a new stake in shares of Humacyte in the fourth quarter worth approximately $25,000. Atom Investors LP purchased a new position in Humacyte during the 4th quarter valued at $25,000. Truist Financial Corp bought a new position in Humacyte in the 3rd quarter valued at $28,000. Prudential Financial Inc. purchased a new stake in Humacyte in the second quarter worth $28,000. Finally, Financial Advisors Network Inc. bought a new stake in shares of Humacyte during the second quarter worth $28,000. Institutional investors own 44.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. BTIG Research dropped their target price on Humacyte from $3.00 to $2.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Benchmark decreased their price target on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, January 21st. D. Boral Capital restated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research report on Tuesday, April 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Humacyte in a research note on Friday, April 10th. Finally, Wall Street Zen upgraded shares of Humacyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.57.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.